anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composite therapeutic material is produced by bringing together in an aqueous medium tribasic calcium and/or magnesium orthophosphate as defined and silicic acid, formed from a water soluble silicate, either or both being preformed or produced in situ, converting the silicic acid into silica gel, filtering and drying the product.  The tribasic phosphates are defined as including phosphates of higher basicity such as calcium hydroxy phosphate 3Ca3 P2 O8-Ca(OH)2 as well as tribasic calcium and/or magnesium orthophosphate.  Thus a suspension of calcium phosphate in alkali silicate may be mixed with acids, e.g., hydrochloric, nitric, phosphoric or acetic; a solution or partial solution of calcium phosphate in acids may be mixed with alkali silicate solution; a mixed slurry of freshly precipitated calcium phosphate and freshly formed silicic acid may be made; a phosphoric acid solution may be mixed with a suspension of calcium hydroxide in a solution of sodium silicate.  The mixtures are heated to convert silicic acid to silica gel, washed to remove soluble salts, filtered, dried, ground and sifted.ALSO:A composite therapeutic material is produced by bringing together in an aqueous medium tribasic calcium and/or magnesium orthophosphate, as defined, and silicic acid, formed from a water-soluble silicate, either or both being preformed or produced in situ, converting the silicic acid into silica gel, filtering and drying the product.  The tribasic phosphates are defined as including phosphates of higher basicity such as calcium hydroxy phosphate 3Ca3P2O8Ca(OH)2 as well as tribasic calcium and/or magnesium orthophosphate.  Thus, a suspension of calcium phosphate in alkali silicate may be mixed with acids, e.g. hydrochloric, nitric, phosphoric or acetic; a solution or partial solution of calcium phosphate in acids may be mixed with alkali silicate solution; a mixed slurry of freshly precipitated calcium phosphate and freshly formed silicic acid may be made; a phosphoric acid solution may be mixed with a suspension of calcium hydroxide in a solution of sodium silicate.  The mixtures are heated to convert silicic acid to silica gel, washed to remove soluble salts, filtered, dried, ground and sifted.
INTRODUCTION: To provide competent care to patients with autism spectrum disorder (ASD) or intellectual developmental disorder (IDD), healthcare professionals must recognize the needs of neurodivergent populations and adapt their clinical approach. We assessed the perceived preparedness of medical students to adapt care delivery for patients with ASD/IDD, as well as their perceptions on neurodiversity education.
METHODS: We conducted a sequential explanatory mixed-methods study on undergraduate medical students at McGill University during the academic year 2020-2021. We administered an online survey, followed by semi-structured interviews. We analyzed data using descriptive statistics and thematic analysis. We integrated findings at the interpretation level.
RESULTS: We included two-hundred-ten survey responses (~29% of class), and 12 interviews. Few students felt prepared to adjust care for patients with ASD/IDD despite most indicating doing so was important. Ninety-seven percent desired more training regarding care accommodation for neurodivergent patients. Thematic analysis unveiled the perception of current insufficient education, and the value of experiential learning.
DISCUSSION/CONCLUSIONS: This study highlights low perceived preparedness of medical students to accommodate care for neurodivergent patients, and a desire for more instruction. Incorporating interactive training in medical school curricula regarding modifying care delivery for neurodivergent individuals may improve the perceived preparedness of medical trainees to work with these patients and care quality.
The AnemEE study is a population-based cross-sectional survey of children (6-59 months), adult women of reproductive age (15-49 years) and adult males (15-49 years) in six regions of Ethiopia (Afar, Amhara, Tigray, Oromia, Southern Nations, Nationalities and Peoples' Region and Addis Ababa). The study will enroll approximately 5,100 participants and will be conducted in two survey rounds; one survey round in the Belg season and one survey round in the Meher season. All participants will have hemoglobin assessed and will have standardized questionnaires administered to assess sociodemographic, diet, morbidity, and other health/nutrition factors. All participants will also have assessments of anthropometric measures, malaria, and soil transmitted helminth infection. A subset of participants will also have serum ferritin, CRP, AGP, vitamin B12, and folate concentrations assessed. The study data will be used to determine the relative contributions of risk factors for anemia.
Patients receive veliparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, patients are taken off treatment for 1 week and may then continue to recieve veliparib along with carboplatin IV over 30 minutes on day 1 of each cycle. Cycles repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and may optionally undergo biopsies throughout the study. Patients undergo blood sample collection during screening and on study.
Rare demyelinating diseases are a group of diseases whose pathogenesis is based on the process of demyelination. This group of diseases includes acute multiple encephalomyelitis (ADEM), opticoneuromyelitis spectrum diseases (NMOSD) and anti-myelin-oligodendrocyte glycoprotein-associated diseases (MOG-antibodies-associated diseases - MOGAD). Recently, new biological drugs for pathogenetic therapy have been developed, which have shown their effectiveness and good tolerability in comparison with therapy with first- and second-line drugs. Aim of the study - analysis of modern possibilities of pathogenetic treatment of patients with ADEM, seronegative and seropositive patients with NMOSD. The analysis was carried out on the basis of English-language publications in PubMed published over the past five years. This review summarizes current ideas about the possibilities of pathogenetic treatment of rare diseases. The advantages of using ravulizumab over other representatives of a new biological therapy associated with the use of monoclonal antibodies are shown. The analyzed data allow us to conclude that there is a significant development of pathogenetic treatment options for ZSONM. However, the effectiveness of new therapeutic biological drugs is still limited due to the lack of a large amount of clinical data to confirm, which creates the need to continue analyzing the experience of their use.
Multivalent D-peptidic compoimds that specifically bind to a target protein are provided. The multivalent D-peptidic compounds can include two or more distinct variant D-peptidic domains connected via linking components. The D-peptidic compounds can include multiple distinct domains that specifically bind to different binding sites on a target protein to provide for high affinity binding to, and potent activity against, the target protein. D-peptidic variant GA and Z domain polypeptides are also provided, which polypeptides have specificity-determining motifs (SDM) for specific binding to a target protein, such as VEGF-A or PD-1. In some embodiments where the target protein is homodimeric (e.g., VEGF-A, PD-1), the D-peptidic compounds may be similarly dimeric, and include a dimer of multivalent (e.g., bivalent) D-peptidic compounds. Methods for using the compounds are provided, including methods for treating a disease or condition associated with a target protein in a subject.
BACKGROUND: Many complex abdominal hernias are referred to tertiary academic institutions for evaluation and treatment. The purpose of this study was to compare clinical outcomes from complex abdominal hernia repairs and abdominal wall reconstructions at a community hospital vs high volume academic centers participating in Abdominal Core Health Quality Collaborative (ACHQC).
METHODS: Patients undergoing elective complex abdominal hernia repair were identified in our community setting and treated between 2016 and 2019. These results were then compared to Academic centers in the ACHQC database. Complex hernia definition was limited to those who have undergone any myofascial advancement procedure for homogeneity. Informed consent was obtained, and study was IRB approved. All data was de-identified.
RESULTS: A total of 180 patients underwent complex abdominal hernia repair at our community hospital. The ACHQC database identified 6299 patients meeting criteria at participating academic centers. Demographics were similar between the two groups including hernia grade, size and wound class. Academic centers tended to have patients with previous component separations (25.7% vs 10.6%) and immunosuppressed (7.2% vs 2.8%), while the community hospital patients included more patients with tobacco use (18.9% vs 12.1%) and hypertension (65% vs 54.9%). Operative times were significantly less at the community hospital, patients requiring >240 minutes of time for repair at academic centers (39.6% vs 5%). Postoperatively length of stay was significantly shorter at the community hospital group averaging 3.7 days vs academic centers of 6 days (P < .05). Although overall complications were less in the community hospital group (26.5% vs 19.4%). Readmission within 30 days was nearly twice as frequent in the community hospital group (14.4% vs 7.7%).
CONCLUSION: Community hospitals can provide comparable care and surgical expertise as major academic centers in regard to complex hernias in a large majority of cases. There is a need for dedicated care coordination and continuous review of supporting staff and outcomes is necessary to assure quality care. There is still a need to identify which patients would benefit from treatment at an academic center as opposed to a community hospital in order to maximize patient access and outcomes at both types of hospital setting. Further investigation needs to be performed regarding criteria for which patients should be transferred to academic centers for their complex hernia care. Identifying patients who would benefit from treatment at Academic Centers as opposed to Community hospitals should continue to be investigated.
OBJECTIVES: The purpose of this study was to retrospectively assess cystic changes in findings on follow-up CT scans of patients with fibrotic nonspecific interstitial pneumonia (NSIP).
METHODS: The initial and last high-resolution CT scans of 58 patients with pathologically proven fibrotic NSIP were evaluated retrospectively. The median follow-up periods were 48 months (range, 12-183 months). The pattern, extent, and distribution of abnormal CT findings were compared with findings in the same region on previous and subsequent CT scans with a focus on cystic lesions.
RESULTS: Cystic lesions in a cluster were shown in 16 patients (28%) with fibrotic NSIP on the last CT scans. Focal clustered cysts were found in 5 cases and diffuse clustered cysts were seen in 11 cases. Focal clustered cysts mimicked honeycombing seen in usual interstitial pneumonia (UIP). Diffuse cysts were uniform in size in 7 of the 11 cases. Traction bronchiectasis in a cluster was seen in 3 of the 7 cases. The clustered cystic changes on CT during the course of NSIP mainly consisted of traction bronchiectasis and bronchiolectasis.
CONCLUSIONS: Long-standing NSIP did not form honeycombing. The clustered cysts in patients with fibrotic NSIP were mainly remodeling of bronchiectasis.
The present invention provides a compound which is an ester of a polyglycerol, a fatty acid and a dicarboxylic acid, wherein the following requirements (A) to (D) are satisfied. (A) The average polymerization degree of the polyglycerol is 2 to 20. (B) The total ratio of branched fatty acids and unsaturated fatty acids having 18 to 22 carbon atoms in all fatty acids is 70% by mass or more. (C) The mass ratio (polyglycerol:fatty acid) of the polyglycerol to the fatty acid is 1:0.7 to 1:1.5. (D) The dicarboxylic acid has 4 to 12 carbon atoms; and the molar ratio (dicarboxylic acid/polyglycerol) of the dicarboxylic acid to the polyglycerol is 0.01 to 0.30. The present invention is able to provide a novel compound which is suppressed in eye irritancy and has excellent stability without being separated if added into an ester oil.
PROBLEM TO BE SOLVED: To provide a method for forming a coated base sheet which exhibits extremely low speed dissolution and releasing of a coated radioisotope and is suitable for use in medical applications. SOLUTION: A method for coating a base sheet with a radioisotope is provided. In this case, it consists of a process wherein the base sheet is immersed into a soln. contg. γ, β<+> , α or β<-> releasing radioisotope, a process wherein this base sheet is exposed to conditioning vibration cavitation to produce a coated base sheet, a process wherein the coated base sheet is calcined at a temp. below the recrystallization temp. of the base sheet, a process wherein the coated base sheet is rinsed and a process wherein the coated base sheet is dried.
PCT No. PCT/US91/00696 Sec. 371 Date Jul. 31, 1992 Sec. 102(e) Date Jul. 31, 1992 PCT Filed Feb. 1, 1991 PCT Pub. No. WO91/11464 PCT Pub. Date Aug. 8, 1991.An antibody to septin, in which septin is an opsonin. Septin is isolated from human serum and is present at high levels in normal serum in distinction to the acute phase protein lipoprotein binding protein (LBP). Septin is an opsonin that is capable of binding to lipopolysaccharide to form a complex that is recognized by a receptor on monocytes, macrophage cells and polymorphonuclear cells, and that possesses an apparent molecular weight of about 90 kD as determined by SDS-PAGE analysis. Utilities of the antibody are provided, and testing procedures, materials in kit form, recombinant materials and procedures, and compositions are likewise set forth.
The efficacy of diclofenac potassium for oral solution in the acute treatment of migraine headache was demonstrated in two randomized, double-blind, placebo-controlled trials.

Patients enrolled in these two trials were predominantly female (85%) and white (86%), with a mean age of 40 years (range: 18 to 65). Patients were instructed to treat a migraine of moderate to severe pain with 1 dose of study medication. Patients evaluated their headache pain 2 hours later. Associated symptoms of nausea, photophobia, and phonophobia were also evaluated. In addition, the proportion of patients who were "sustained pain free", defined as a reduction in headache severity from moderate or severe pain to no pain at 2 hours post-dose without a return of mild, moderate, or severe pain and no use of rescue medication for 24 hours post-dose, was also evaluated. In these studies, the percentage of patients achieving pain freedom 2 hours after treatment and sustained pain freedom from 2 to 24 hours post-dose was significantly greater in patients who received diclofenac potassium for oral solution compared with those who received placebo (see Table 3). The percentage of patients achieving pain relief 2 hours after treatment (defined as a reduction in headache severity from moderate or severe pain to mild or no pain) was also significantly greater in patients who received diclofenac potassium for oral solution compared with those who received placebo (see Table 3). 

The estimated probability of achieving migraine headache pain freedom within 2 hours following treatment with diclofenac potassium for oral solution is shown in Figure 1.

Figure 1: Percentage of Patients with Initial Headache Pain Freedom within 2 Hours

There was a decreased incidence of nausea, photophobia and phonophobia following administration of diclofenac potassium for oral solution, compared to placebo. The efficacy and safety of diclofenac potassium for oral solution was unaffected by age or gender of the patient.
This group will walk 4 days a week along with high-intensity interval training. Evaluations will be made before and after.
PCT No. PCT/US94/05930 Sec. 371 Date May 4, 1995 Sec. 102(e) Date May 4, 1995 PCT Filed May 26, 1994 PCT Pub. No. WO94/27557 PCT Pub. Date Dec. 8, 1994A chewable tablet comprises a medicament dispersed in a chewable base, such as mannitol, together with an effervescent couple, such as citric acid-sodium bicarbonate. The combination of effervescence and chewability with optional flavorings improves the taste characteristics of the medicament in oral administration. A distintegrant such as microcrystalline cellulose may be added to give the patient the option of dispersing the tablet in water.
Partners of patients with advanced cancer often take a great responsibility for the patient's care. They are often unprepared for a situation where they are faced both with the role as caregivers and with the patient's impending death. This lack of preparedness has been associated with psychological and physical unhealth. Interventions delivered by multi-professional palliative care teams have proved to be effective both in promoting preparedness for caregiving, death and the continued life of the bereaved. This project holds significant research questions on how to implement an intervention and make it easily available to all those in need and prevent negative consequences related to caregiving and the loss of a partner. To reach as many partners as possible, a web-based intervention has been developed on a website (närstående.se) which consists of supportive films and text as well as an online forum. The films show conversations between partners (actors) and healthcare professionals (authentic). The conversations concern potentially modifiable topics, such as medical issues and communication, that are associated with preparedness. The project will study the effects of proactive telephone calls that will be delivered to partners with the aim to support their use of the website. Instruments for measuring outcomes will be available both on paper or electronically. To obtain data for the main outcomes, preparedness for caregiving and for death, 200 partners will be recruited and get access to the website. They will also receive a telephone call with instructions on how to use the website and have access to technical support if necessary. Preparedness for caregiving will be measured at baseline and four weeks later (pre- and post-intervention). Preparedness for death will be measured eight weeks after the patient's death. The status of the modifiable topics will be measured at baseline and four weeks later. Physical and psychological health of the partner will be measured one year later. Further, semi-structured interviews will be performed with participants to explore the feasibility and acceptibility of the web intervention. The project will add significant knowledge about whether web-based support has the potential to increase preparedness and decrease negative consequences for partners of patients with advanced cancer during ongoing care and after the patient's death. Because current trends point towards increased levels of home-care, web-based interventions could be a way to reach more partners in a more cost-effective way. This project is meant to be a pilot to a larger study with a randomised controlled design.
Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
The invention belongs to the technical field of high molecular materials, and in particular relates to preparation of a degradable environmental sensitive polymer nano hydrogel and an application. According to the invention, the degradable multiple environmental sensitive polymer nano hydrogel is obtained through precipitation polymerization by taking N-vinyl caprolactam as a main monomer, N, N'-di(acrylyl) cystamine as a crosslinking agent as well as hydrophilic monomers such as methylacrylic acid, hydroxymethyl acrylamide, polyethylene glycol monomethyl ether metacrylic acid ester (Mw=2000) as comonomers. According to the invention, the raw materials are easily-available, and the preparation method is simple. According to the method, water is used as the solvent, so that the method is environment-friendly. The polymer nano hydrogel prepared is good in dispersibility, uniform in size, and good in stability and biocompatibility. The phase inversion temperature of the polymer can be adjusted by controlling the use levels of methylacrylic acid, N-hydroxymethyl acrylamide and polyethylene glycol monomethyl ether metacrylic acid ester and the pH value of the environment. Therefore, the hydrogel can be applied to release of medicines in fixed points and is used as a carrier for targeted release of medicines.
PURPOSE: SCF analogs having enhanced biological activity and stability are preferable to customers because smaller amount of administration can be used to obtain same biological result. Also the analogs are preferable to producers because more units of product are sold due to more active products. Enhancement of stability, especially enhancement of preservation time is especially useful for both of customers and producers. CONSTITUTION: SCF analogs containing substituted Asp instead of Asn at position 10 and position 11(according to the numbering of Fig. 1) have substantially higher biological activities and enhanced stability compared to unmodified SCFs. The SCF analogs are more stable than wild type and have enhanced biological activities, and remove any dangers related to deamination.
PURPOSE:To obtain a cured body which rapidly cures at about neutral pH and has high strength and excellent bio-affinity by constituting the cured matter of the cement compsn. contg. a specific powder material mixture consisting of alpha type calcium ternary phosphate and calcium primary phosphate and a hardening liquid and further compounding water-soluble sodium salts with this compsn. CONSTITUTION:This hydraulic calcium phosphate cement compsn. is constituted of the cement compsn. contg. the powder material mixture of 1.400 to 1.498Ca/P molar ratio of the alpha type calcium ternary phosphate and calcium primary phosphate and the hardening liquid, In addition, the water-soluble sodium salts are incorporated into the above-mentioned powder material mixture and/or hardening liquid. The above-mentioned curing liquid is not particularly limited and is exemplified by, for example, water. The water-soluble sodium salts are exemplified by, for example, sodium succinate, sodium lactate, sodium acetate, sodium chloride, etc.